pharma& to Highlight Subsequent Therapy Data for Rubraca® (rucaparib) in Patients with Advanced Ovarian Cancer at ESMO-GYN Congress 2026

Intended for the healthcare media

Vienna, Austria, June 3, 2026 – pharmaand GmbH (pharma&), a global company dedicated to preserving the availability and fostering the further development of essential medicines to leave no patient behind, today announced subsequent therapy data for Rubraca® (rucaparib) in patients with advanced ovarian cancer will be presented in a rapid oral presentation during the **European Society for Medical Oncology (ESMO)'s Gynaecological Cancers Congress 2026,** June 17-19 in Copenhagen, Denmark.

> **Title:** Subsequent Anti-Cancer Therapy of Patients with Newly Diagnosed Advanced Ovarian Cancer in ATHENA-MONO/GOG-3020/ENGOT-ov45
> **Presenter and Lead Author**: Dr. Emily Prendergast, MD, Cedars-Sinai, Los Angeles, CA, U.S.
> **Time and Date:** 2:45 p.m. CEST, Wednesday, June 17
> **Location**: Auditorium D1, Bella Center Copenhagen

Attendees can **visit pharma& at booth 10** in the **Exhibition Hall**.

About the ATHENA Clinical Trial

ATHENA (GOG 3020/ENGOT-ov45) (NCT03522246) is an international, randomized, double-blind, phase III trial consisting of two separate and fully independently powered study comparisons evaluating rucaparib monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment for patients with newly diagnosed advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. ATHENA enrolled approximately 1000 patients across 24 countries, all women with newly diagnosed ovarian cancer who responded to their first-line chemotherapy. The trial completed accrual in 2020 and was conducted in association with the GOG Foundation, Inc. (GOG-F) in the U.S. and the European Network of Gynaecological Oncological Trial groups (ENGOT) in Europe. GOG-F and ENGOT are the two largest cooperative groups in the U.S. and Europe dedicated to the treatment of gynecological cancers.

ATHENA-MONO is evaluating the benefit of rucaparib monotherapy versus placebo in 538 women in this patient population. The primary efficacy analysis evaluated two prospectively defined molecular sub-groups in a step-down manner: 1) HRD-positive (inclusive of BRCA mutant) tumors, and 2) the intent-to-treat population, or all patients treated in ATHENA-MONO.

###

About pharma& (pharmaand.com)
pharmaand GmbH (pharma&), a privately owned global company, aspires to breathe new life into proven medicines. The Company is dedicated to preserving the availability and fostering the further development of essential medicines worldwide to leave no patient behind. Since its inception, pharma& has acquired and integrated 10+ medicines, expanding its portfolio across a wide range of therapy areas, with an increasing focus on hematology and oncology treatments. The Company's unique synthesis of subsidiaries, joint ventures, and partners enables pharma& to provide its portfolio of medicines to eligible patients worldwide by spanning the continuum of research and development, in-house product and active pharmaceutical ingredients (API) manufacturing, distribution via its global partner network, healthcare provider engagement, patient safety services, and patient access services through U.S. Market Access.

# # #

pharma& Media Contact:
media@pharmaand.com